Epstein-Barr virus associated disease following blood or marrow transplant.
EBV associated disease continues to be a problem in the post-BHT population. The pathogenesis, risk factors, and diagnosis of PTLD, as well as the rationale, efficacy and advantages/disadvantages of various prophylactic, pre-emptive and treatment strategies are discussed.
Gross
Thomas G
TG
Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital Medical Center, 700 Children's Drive, Cincinnati, OH 43205-2696, USA. Tgross@chi.osu.edu
Loechelt
Brett J
BJ
D001803:Blood Transfusion; D016026:Bone Marrow Transplantation / Q000276:immunology*; D020031:Epstein-Barr Virus Infections / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000628:therapy / Q000821:virology*; D012307:Risk Factors